Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2021/11/037820
CTRI/2021/11/037820RecruitingPhase 2

Phase II study of hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed IDHwt Anaplastic Astrocytoma (NCI-R-01-HyRAA) - NCI-R-01-HyRAA

AIIMS0 sites0 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 2
Status
Recruiting
Sponsor
AIIMS
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •Age 18 - 65 years
  • •Patients of either sex will be included
  • •Karnofsky performance score 70 and above
  • •Biopsy proven Anaplastic Astrocytoma (WHO grade III), 1p19q non-co deleted (IDH wt, ATRX retained or lost).
  • •Baseline investigations [LFT, RFT, complete blood count] should be within normal limits Hemoglobin >10gm/dl, Platelet >100000, TLC-4000-11000
  • •No history of prior anti-cancer treatment with radiotherapy, chemotherapy, or surgery
  • •The patient must sign an informed consent before entry into the study

Exclusion Criteria

  • •Age >65 years and <18 years
  • •Unresectable disease
  • •Previous history of neurosurgery or radiotherapy
  • •Recurrent disease
  • •Patients with significant co-morbid condition
  • •History of previous malignancy
  • •Karnofsky Performance score below 70
  • •Not compliant for regular follow up

Investigators

Sponsor
AIIMS

Similar Trials

Recruiting
Phase 2
imited fraction radiation in anaplastic astrocytoma
CTRI/2021/08/035719AIIMS
Recruiting
Phase 3
Phase III trial of hypo-fractionated accelerated intensity modulated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed Glioblastoma (HYART-GBM)
CTRI/2020/06/025573AIIMS New Delhi
Completed
Not Applicable
Phase I-/II-study of Hyperfractionated-Accelerated Radiation Therapy plus Cetuximab plus Cisplatin chemotherapy in locally advanced inoperable squamous cell cancers of head and neckCancer
ISRCTN47339346Martin-Luther-University Halle-Wittenberg (Germany)92
Not yet recruiting
Phase 2
A study comparing Hypofractionated Radiotherapy (HART) with Conventional Fractionated Radiotherapy (CFRT) in Newly Diagnosed High Grade Glioma (HGG)
CTRI/2024/03/064914Department of Radiotherapy and Oncology, Postgraduate Institute of Medical Education and Research
Active, not recruiting
Phase 1
A clinical Phase I/II-study of radiation therapy (HART(hyperfractionated-accelerated radiation)) plus chemotherapy (cetuximab (CET) and cisplatin (CIS)) in locally advanced inoperable skin cancers of head and neck.Squamous cell cancer of head and neck, unresectable, locally advanced, Stage III/IVa or b (UICC, 2002)MedDRA version: 14.0Level: LLTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2005-000355-15-DEMartin-Luther-Universität Halle-Wittenberg86